Seeking Alpha·Sep 9, 2026
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks TranscriptCelcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity's FDA approval of gedatolisib (REVTORPYK) marks a pivotal transition from clinical to commercial stage, but the company's financial position is severely strained. Operating losses have widened to -$66.1M in 2026Q2, and total debt surged to $754.4M, dr...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$1.44-24.1% vs -$1.16 | — vs $4M |
Q2 2026 May 14, 2026 | -$0.97+6.7% vs -$1.04 | — vs $3M |
Q2 2026 Mar 25, 2026 | -$0.97+8.5% vs -$1.06 | — vs $1M |
Q4 2025 Nov 12, 2025 | -$0.92+9.8% vs -$1.02 | — vs — |
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also
Benchmark CELC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Celcuity Inc. (CELC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $79.99 | $3.9B | -21.16 | — | — | -163.8% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $24.45 | $3.98B | -28.10 | 48.29% | -229.92% | -25.74% | — | |
| $1.37 | $73.06M | -0.93 | — | — | -78.11% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — |
Celcuity Inc. (CELC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Celcuity Inc. (CELC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 26, 2026·SEC
Aug 13, 2026·SEC
Jul 15, 2026·SEC
Get notified when CELC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Celcuity Inc. (CELC) stock FAQ — growth, dividends, profitability & financials explained
Celcuity Inc. (CELC) reported a net loss of $226.5M for fiscal year 2025.
Celcuity Inc. (CELC) has a return on equity (ROE) of -163.8%. Negative ROE indicates the company is unprofitable.
Celcuity Inc. (CELC) had negative free cash flow of $192.2M in fiscal year 2025, likely due to heavy capital investments.
